Company Overview

Pulse Biosciences, Inc. is a clinical-stage medical technology company focused on developing and commercializing non-thermal tissue ablation solutions based on its proprietary nanosecond pulsed electric field (nsPEF) technology. The company operates primarily within the medical devices and biomedical technology industries, with applications spanning dermatology, aesthetic medicine, oncology, and cardiac and soft tissue treatments. Its technology is designed to clear unwanted or diseased cells while preserving surrounding tissue structures, differentiating it from traditional thermal-based ablation methods.

The company’s primary revenue drivers are expected to be future sales of capital equipment, disposable applicators, and related services once regulatory approvals and broader commercialization are achieved. Pulse Biosciences targets physicians, hospitals, specialty clinics, and aesthetic practices as its key customer segments. Founded in 2004, the company evolved from early research into bioelectric effects on cells and transitioned into a publicly traded company through its NASDAQ listing. Its development has been characterized by long-cycle clinical research, regulatory engagement, and technology refinement rather than near-term commercial scale.

Business Operations

Pulse Biosciences operates as a single reportable operating segment, focused on the research, development, and anticipated commercialization of nsPEF-based medical systems. The company generates minimal revenue and remains primarily funded through equity financing, reflecting its pre-commercial and clinical-stage status. Its core assets include proprietary pulse generation systems, electrode designs, and treatment protocols that together form its nsPEF platform.

Operations are primarily domestic, with research, engineering, and administrative functions centered in the United States, supported by international clinical studies and limited overseas activities. The company controls its core intellectual property portfolio internally and collaborates with clinical investigators, research institutions, and contract manufacturers. No material joint ventures have been disclosed in public filings, and commercialization efforts to date have focused on controlled market releases and clinical evaluation programs rather than full-scale distribution.

Strategic Position & Investments

Strategically, Pulse Biosciences is focused on advancing its nsPEF technology toward regulatory clearance and commercial adoption, with near- and mid-term emphasis on dermatology and aesthetic indications, where regulatory pathways and adoption cycles may be more favorable. Growth initiatives center on expanding clinical data, refining system usability, and developing next-generation platforms tailored to specific indications.

The company has made targeted investments in internal research and development rather than pursuing large-scale acquisitions. Its portfolio is concentrated on proprietary platforms rather than diversified subsidiaries, reflecting a strategy of depth over breadth. Emerging areas of interest include additional soft tissue applications and potential future use in oncology and cardiac therapies, though broader expansion remains dependent on clinical outcomes and regulatory progress.

Geographic Footprint

Pulse Biosciences is headquartered in Hayward, California, which serves as the center for executive leadership, research and development, and corporate operations. The company’s primary operational footprint is within North America, where the majority of its employees, facilities, and clinical collaborations are located.

Internationally, the company has conducted and continues to support clinical studies in Europe, contributing to its regulatory and scientific strategy. While it does not maintain a broad commercial infrastructure outside the United States, its technology development and clinical engagement give it an emerging presence in key global medical technology markets.

Leadership & Governance

Pulse Biosciences was founded by Mark B. Schoen, whose background in medical device innovation helped shape the company’s focus on bioelectric medicine. The leadership team emphasizes long-term technology development, clinical validation, and disciplined capital allocation consistent with a clinical-stage public company.

Key executives include:

• Paul A. LaViolette – President & Chief Executive Officer
• Michael J. Foltz – Chief Financial Officer
• Mark B. Schoen – Founder & Executive Chairman

The leadership’s strategic vision centers on establishing nsPEF as a differentiated therapeutic modality through rigorous science, regulatory compliance, and phased market entry.